Immunology in tuberculosis: Challenges in monitoring of disease activity and identifying correlates of protection

Current Pharmaceutical Design

Volumn 17, Issue 27, 2011, Pages 2853-2862

  van Altena, Richard ^a   Duggirala, Sridevi ^a   Gröschel, Matthias I P ^a   van der Werf, Tjip S ^a,b  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

BCG; Immune response; Immune response inflammatory syndrome; Interferon gamma; Iron; Mycobacterium tuberculosis; Vitamin D

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; BCG VACCINE; CAPREOMYCIN; CATHELICIDIN; CLARITHROMYCIN; CLOFAZIMINE; COLECALCIFEROL; CULTURE FILTRATE PROTEIN 10; CYCLOSERINE; DOXERCALCIFEROL; EARLY SECRETORY ANTIGENIC TARGET 6; ETHAMBUTOL; ETHIONAMIDE; IMIPENEM; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; LINEZOLID; MOXIFLOXACIN; OFLOXACIN; PROTIONAMIDE; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; THIOACETAZONE; VITAMIN D;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; BACTERIAL LOAD; BCG VACCINATION; CYTOKINE RELEASE; DISEASE ACTIVITY; DRUG TREATMENT FAILURE; GENETIC SUSCEPTIBILITY; HOST PATHOGEN INTERACTION; HOST SUSCEPTIBILITY; HUMAN; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; MIXED INFECTION; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; TUBERCULOSIS; VITAMIN D DEFICIENCY;

EID: 80053490215     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161211797470228     Document Type: Article

References (154)

1. Zink AR, Sola C, Reischl U, et al. Characterization of Mycobacterium tuberculosis complex DNAs from Egyptian mummies by spoligotyping. J Clin Microbiol 2003; 41: 359-67.
2. Donoghue HD, Spigelman M, Greenblatt CL, et al. Tuberculosis: from prehistory to Robert Koch, as revealed by ancient DNA. Lancet Infect Dis 2004; 4: 584-92.
3. Smith NH, Hewinson RG, Kremer K, Brosch R, Gordon SV. Myths and misconceptions: the origin and evolution of Mycobacterium tuberculosis. Nat Rev Microbiol 2009; 7: 537-44.
4. Brosch R, Gordon SV, Marmiesse M, et al. A new evolutionary scenario for the Mycobacterium tuberculosis complex. Proc Natl Acad Sci U S A 2002; 99: 3684-9.
5. Kaufmann SH, Cole ST, Mizrahi V, Rubin E, Nathan C. Mycobacterium tuberculosis and the host response. J Exp Med 2005; 201: 1693-7.
6. Comas I, Chakravartti J, Small PM, et al. Human T cell epitopes of Mycobacterium tuberculosis are evolutionarily hyperconserved. Nat Genet 2010; 42: 498-503.
7. Russell DG. Who puts the tubercle in tuberculosis? Nat Rev Microbiol 2007; 5: 39-47.
8. [Hett EC, Rubin EJ. Bacterial growth and cell division: a mycobacterial perspective. Microbiol Mol Biol Rev 2008; 72: 126-56, table.
9. Dye C, Williams BG. The population dynamics and control of tuberculosis. Science 2010; 328: 856-61.
10. Kaufmann SH. Robert Koch, the Nobel Prize, and the ongoing threat of tuberculosis. N Engl J Med 2005; 353: 2423-6.
11. Anonymus. Controlled clinical trial of short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis. Lancet 1972; 1: 1079-85.
12. Dheda K, Lampe FC, Johnson MA, Lipman MC. Outcome of HIVassociated tuberculosis in the era of highly active antiretroviral therapy. J Infect Dis 2004; 190: 1670-6.
13. Harries AD, Chimzizi R, Zachariah R. Safety, effectiveness, and outcomes of concomitant use of highly active antiretroviral therapy with drugs for tuberculosis in resource-poor settings. Lancet 2006; 367: 944-5.
14. Dheda K, Shean K, Zumla A, et al. Early treatment outcomes and HIV status of patients with extensively drug-resistant tuberculosis in South Africa: a retrospective cohort study. Lancet 2010; 375: 1798-807.
15. Harries AD, Zachariah R, Corbett EL, et al. The HIV-associated tuberculosis epidemic--when will we act? Lancet 2010; 375: 1906-19.
16. Khan FA, Minion J, Pai M, Royce S, Burman W, Harries AD, Menzies D. Treatment of active tuberculosis in HIV-coinfected patients: a systematic review and meta-analysis. Clin Infect Dis 2010; 50: 1288-99.
17. Gandhi NR, Nunn P, Dheda K, et al. Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis. Lancet 2010; 375: 1830-43.
18. [WHO. Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 global report on surveillance and response 2010
19. Cohen T, Sommers B, Murray M. The effect of drug resistance on the fitness of Mycobacterium tuberculosis. Lancet Infect Dis 2003; 3: 13-21.
20. Nathanson E, Nunn P, Uplekar M, et al. MDR Tuberculosis - Critical Steps for Prevention and Control. N Engl J Med 2010; 363: 1050-8.
21. Homolka S, Niemann S, Russell DG, Rohde KH. Functional genetic diversity among Mycobacterium tuberculosis complex clinical isolates: delineation of conserved core and lineage-specific transcriptomes during intracellular survival. PLoS Pathog 2010; 6: e1000988.
22. Parwati I, van Crevel R, van Soolingen D. Possible underlying mechanisms for successful emergence of the Mycobacterium tuberculosis Beijing genotype strains. Lancet Infect Dis 2010; 10: 103-11.
23. Groenewald P, Bradshaw D, Daniels J, et al. Local-level mortality surveillance in resource-limited settings: a case study of Cape Town highlights disparities in health. Bull World Health Organ 2010; 88: 444-51.
24. den Boon S, van Lill SW, Borgdorff MW, et al. High prevalence of tuberculosis in previously treated patients, Cape Town, South Africa. Emerg Infect Dis 2007; 13: 1189-94.
25. Chambers ST, Hendrickse WA, Record C, Rudge P, Smith H. Paradoxical expansion of intracranial tuberculomas during chemotherapy. Lancet 1984; 2: 181-4.
26. Cheng VC, Ho PL, Lee RA, et al. Clinical spectrum of paradoxical deterioration during antituberculosis therapy in non-HIV-infected patients. Eur J Clin Microbiol Infect Dis 2002; 21: 803-9.
27. Breen RA, Smith CJ, Bettinson H, et al. Paradoxical reactions during tuberculosis treatment in patients with and without HIV coinfection. Thorax 2004; 59: 704-7.
28. Carvalho AC, De Iaco G, Saleri N, et al. Paradoxical reaction during tuberculosis treatment in HIV-seronegative patients. Clin Infect Dis 2006; 42: 893-5.
29. Cheng SL, Wang HC, Yang PC. Paradoxical response during antituberculosis treatment in HIV-negative patients with pulmonary tuberculosis. Int J Tuberc Lung Dis 2007; 11: 1290-5.
30. Rand L, Green JA, Saraiva L, Friedland JS, Elkington PT. Matrix metalloproteinase-1 is regulated in tuberculosis by a p38 MAPKdependent, p-aminosalicylic acid-sensitive signaling cascade. J Immunol 2009; 182: 5865-72.
31. Maartens G, Wilkinson RJ. Tuberculosis. Lancet 2007; 370: 2030-43.
32. Meintjes G, Rangaka MX, Maartens G, Rebe et al. Novel relationship between tuberculosis immune reconstitution inflammatory syndrome and antitubercular drug resistance. Clin Infect Dis 2009; 48: 667-76.
33. Manabe YC, Breen R, Perti T, Girardi E, Sterling TR. Unmasked tuberculosis and tuberculosis immune reconstitution inflammatory disease: a disease spectrum after initiation of antiretroviral therapy. J Infect Dis 2009; 199: 437-44.
34. Meintjes G, Wilkinson RJ. Undiagnosed Active Tuberculosis in HIV-Infected Patients Commencing Antiretroviral Therapy. Clin Infect Dis 2010; 51: 830-2.
35. Haddow LJ, Dibben O, Moosa MY, Borrow P, Easterbrook PJ. Circulating inflammatory biomarkers can predict and characterize tuberculosis-associated immune reconstitution inflammatory syndrome. AIDS 2011; 25: 1163-74.
36. Wergeland I, Assmus J, Dyrhol-Riise AM. T regulatory cells and immune activation in Mycobacterium tuberculosis infection and the effect of preventive therapy. Scand J Immunol 2011; 73: 234-42.
37. Belkaid Y, Tarbell K. Regulatory T cells in the control of host microorganism interactions (*). Annu Rev Immunol 2009; 27: 551-89.
38. Russell DG. Mycobacterium tuberculosis: here today, and here tomorrow. Nat Rev Mol Cell Biol 2001; 2: 569-77.
39. Brodin P, Poquet Y, Levillain F, et al. High Content Phenotypic Cell-Based Visual Screen Identifies Mycobacterium tuberculosis Acyltrehalose-Containing Glycolipids Involved in Phagosome Remodeling. PLoS Pathog 2010; 6: e1001100.
40. Mack U, Migliori GB, Sester M, et al. LTBI: latent tuberculosis infection or lasting immune responses to M. tuberculosis? A TBNET consensus statement. Eur Respir J 2009; 33: 956-73.
41. Gallegos AM, van Heijst JW, Samstein M, Su X, Pamer EG, Glickman MS. A Gamma Interferon Independent Mechanism of CD4 T Cell Mediated Control of M. tuberculosis Infection in vivo. PLoS Pathog 2011; 7: e1002052.
42. Millington KA, Gooding S, Hinks TS, Reynolds DJ, Lalvani A. Mycobacterium tuberculosis-Specific Cellular Immune Profiles Suggest Bacillary Persistence Decades after Spontaneous Cure in Untreated Tuberculosis. Clin Infect Dis 2010; 202: 1685-9.
43. Yang Z, Rosenthal M, Rosenberg NA, et al. How dormant is Mycobacterium tuberculosis during latency? A study integrating genomics and molecular epidemiology. Infect Genet Evol 2011; 11: 1164-7.
44. Ford CB, Lin PL, Chase MR, et al. Use of whole genome sequencing to estimate the mutation rate of Mycobacterium tuberculosis during latent infection. Nat Genet 2011; 43: 482-6.
45. Russell DG, Cardona PJ, Kim MJ, Allain S, Altare F. Foamy macrophages and the progression of the human tuberculosis granuloma. Nat Immunol 2009; 10: 943-8.
46. [Mehra S, Pahar B, Dutta NK, et al. Transcriptional reprogramming in nonhuman primate (rhesus macaque) tuberculosis granulomas. PLoS ONE 2010; 5:
47. Davis JM, Ramakrishnan L. The role of the granuloma in expansion and dissemination of early tuberculous infection. Cell 2009; 136: 37-49.
48. Rubin EJ. The granuloma in tuberculosis--friend or foe? N Engl J Med 2009; 360: 2471-3.
49. Volkman HE, Pozos TC, Zheng J, Davis JM, Rawls JF, Ramakrishnan L. Tuberculous granuloma induction via interaction of a bacterial secreted protein with host epithelium. Science 2010; 327: 466-9.
50. Herbst S, Schaible UE, Schneider BE. Interferon gamma activated macrophages kill mycobacteria by nitric oxide induced apoptosis. PLoS ONE 2011; 6: e19105.
51. Porcelli SA, Jacobs WR, Jr. Tuberculosis: unsealing the apoptotic envelope. Nat Immunol 2008; 9: 1101-2.
52. Bold TD, Banaei N, Wolf AJ, Ernst JD. Suboptimal Activation of Antigen-Specific CD4 Effector Cells Enables Persistence of M. tuberculosis In Vivo. PLoS Pathog 2011; 7: e1002063.
53. Divangahi M, Chen M, Gan H, et al. Mycobacterium tuberculosis evades macrophage defenses by inhibiting plasma membrane repair. Nat Immunol 2009; 10: 899-906.
54. Divangahi M, Desjardins D, Nunes-Alves C, Remold HG, Behar SM. Eicosanoid pathways regulate adaptive immunity to Mycobacterium tuberculosis. Nat Immunol 2010; 11: 751-8.
55. Dheda K, Smit RZ, Badri M, Pai M. T-cell interferon-gamma release assays for the rapid immunodiagnosis of tuberculosis: clinical utility in high-burden vs. low-burden settings. Curr Opin Pulm Med 2009; 15: 188-200.
56. Pai M, Dheda K, Cunningham J, Scano F, O'Brien R. T-cell assays for the diagnosis of latent tuberculosis infection: moving the research agenda forward. Lancet Infect Dis 2007; 7: 428-38.
57. Wallis RS, Pai M, Menzies D, et al. Biomarkers and diagnostics for tuberculosis: progress, needs, and translation into practice. Lancet 2010; 375: 1920-37.
58. Pai M, Minion J, Steingart K, Ramsay A. New and improved tuberculosis diagnostics: evidence, policy, practice, and impact. Curr Opin Pulm Med 2010; 16: 271-84.
59. Chang KC, Leung CC. Systematic review of interferon-gamma release assays in tuberculosis: focus on likelihood ratios. Thorax 2010; 65: 271-6.
60. Diel R, Loddenkemper R, Nienhaus A. Evidence-based comparison of commercial interferon-gamma release assays for detecting active TB: a metaanalysis. Chest 2010; 137: 952-68.
61. Chee CB, KhinMar KW, Gan SH, et al. Tuberculosis treatment effect on T-cell interferon-gamma responses to Mycobacterium tuberculosis-specific antigens. Eur Respir J 2010; 36: 355-61.
62. Mahomed H, Hawkridge, T., Verver S, et al. The Tuberculin Skin Test versus QuantiFERON TB GoldH in Predicting Tuberculosis Disease in an Adolescent Cohort Study in South Africa. PLoS ONE 2011; 6: e17984.
63. Berry MP, Graham CM, McNab FW, et al. An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature 2010; 466: 973-7.
64. Velasco M, Castilla V, Sanz J, et al. Effect of simultaneous use of highly active antiretroviral therapy on survival of HIV patients with tuberculosis. J Acquir Immune Defic Syndr 2009; 50: 148-52.
65. Abdool Karim SS, Naidoo K, Grobler A, et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med 2010; 362: 697-706.
66. Franke MF, Robins JM, Mugabo J, et al. Effectiveness of Early Antiretroviral Therapy Initiation to Improve Survival among HIVInfected Adults with Tuberculosis: A Retrospective Cohort Study. PLoS Med 2011; 8: e1001029.
67. Abel L, Casanova JL. Genetic predisposition to clinical tuberculosis: bridging the gap between simple and complex inheritance. Am J Hum Genet 2000; 67: 274-7.
68. Casanova JL, Abel L. Genetic dissection of immunity to mycobacteria: the human model. Annu Rev Immunol 2002; 20: 581-620.
69. Bellamy RJ, Hill AV. Host genetic susceptibility to human tuberculosis. Novartis Found Symp 1998; 217: 3-13.
70. Bellamy R. Genetics and pulmonary medicine. 3. Genetic susceptibility to tuberculosis in human populations. Thorax 1998; 53: 588-93.
71. Bellamy R. Identifying genetic susceptibility factors for tuberculosis in Africans: a combined approach using a candidate gene study and a genome-wide screen. Clin Sci (Colch) 2000; 98: 245-50.
72. Bellamy R. Susceptibility to mycobacterial infections: the importance of host genetics. Genes Immun 2003; 4: 4-11.
73. [Bellamy R. Genetic susceptibility to tuberculosis. Clin Chest Med 2005; 26: 233-46, vi.
74. Vannberg FO, Chapman SJ, Khor CC, et al. CD209 Genetic Polymorphism and Tuberculosis Disease. PLoS ONE 2008; 3: e1388.
75. Bellamy R, Ruwende C, Corrah T, McAdam KP, Whittle HC, Hill AV. Variations in the NRAMP1 gene and susceptibility to tuberculosis in West Africans. N Engl J Med 1998; 338: 640-4.
76. Thye T, Vannberg FO, Wong SH, et al. Genome-wide association analyses identifies a susceptibility locus for tuberculosis on chromosome 18q11.2. Nat Genet 2010; 42: 739-41.
77. Anonymus. The role of BCG vaccine in the prevention and control of tuberculosis in the United States. A joint statement by the Advisory Council for the Elimination of Tuberculosis and the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep 1996; 45: 1-18.
78. Anonymus. BCG: bad news from India. Lancet 1980; 1: 73-4.
79. [Baily GV. Tuberculosis prevention Trial, Madras. Indian J Med Res 1980; 72 Suppl: 1-74.
80. Anonymus. Fifteen year follow up of trial of BCG vaccines in south India for tuberculosis prevention. Tuberculosis Research Centre (ICMR), Chennai. Indian J Med Res 1999; 110: 56-69.
81. Ponnighaus JM, Fine PE, Sterne JA, et al. Efficacy of BCG vaccine against leprosy and tuberculosis in northern Malawi. Lancet 1992; 339: 636-9.
82. Colditz GA, Berkey CS, Mosteller F, et al. The efficacy of bacillus Calmette-Guerin vaccination of newborns and infants in the prevention of tuberculosis: meta-analyses of the published literature. Pediatrics 1995; 96: 29-35.
83. Eriksen J, Chow JY, Mellis V, et al. Protective effect of BCG vaccination in a nursery outbreak in 2009: time to reconsider the vaccination threshold? Thorax 2010; 65: 1067-71.
84. Lalvani A, Sridhar S. BCG vaccination: 90 years on and still so much to learn. Thorax 2010; 65: 1036-8.
85. Anonymus. BCG vaccine. WHO position paper. Wkly Epidemiol Rec 2004; 79: 27-38.
86. Anonymus. Revised BCG vaccination guidelines for infants at risk for HIV infection. Wkly Epidemiol Rec 2007; 82: 193-6.
87. Hesseling AC, Cotton MF, Marais BJ, et al. BCG and HIV reconsidered: moving the research agenda forward. Vaccine 2007; 25: 6565-8.
88. Jeremiah K, PrayGod G, Faurholt-Jepsen D, et al. BCG vaccination status may predict sputum conversion in patients with pulmonary tuberculosis: a new consideration for an old vaccine? Thorax 2010; 65: 1072-6.
89. Lalor MK, Smith SG, Floyd S, et al. Complex cytokine profiles induced by BCG vaccination in UK infants. Vaccine 2010; 28: 1635-41.
90. Kaufmann SH. Novel tuberculosis vaccination strategies based on understanding the immune response. J Intern Med 2010; 267: 337-53.
91. Kaufmann SH. Future vaccination strategies against tuberculosis: thinking outside the box. Immunity 2010; 33: 567-77.
92. Kaufmann SH. Tuberculosis vaccines--a new kid on the block. Nat Med 2011; 17: 159-60.
93. Dannenberg AM, Jr. Perspectives on clinical and preclinical testing of new tuberculosis vaccines. Clin Microbiol Rev 2010; 23: 781-94.
94. Ratledge C. Iron, mycobacteria and tuberculosis. Tuberculosis (Edinb) 2004; 84: 110-30.
95. Ratledge C, Dover LG. Iron metabolism in pathogenic bacteria. Annu Rev Microbiol 2000; 54: 881-941.
96. Schaible UE, Kaufmann SH. Iron and microbial infection. Nat Rev Microbiol 2004; 2: 946-53.
97. McDermid JM, Prentice AM. Iron and infection: effects of host iron status and the iron-regulatory genes haptoglobin and NRAMP1 (SLC11A1) on host-pathogen interactions in tuberculosis and HIV. Clin Sci (Lond) 2006; 110: 503-24.
98. Boelaert JR, Vandecasteele SJ, Appelberg R, Gordeuk VR. The effect of the host's iron status on tuberculosis. J Infect Dis 2007; 195: 1745-53.
99. Weinberg ED. The development of awareness of iron-withholding defense. Perspect Biol Med 1993; 36: 215-21.
100. Sahiratmadja E, Wieringa FT, van Crevel R, et al. Iron deficiency and NRAMP1 polymorphisms (INT4, D543N and 3'UTR) do not contribute to severity of anaemia in tuberculosis in the Indonesian population. Br J Nutr 2007; 98: 684-90.
101. Gangaidzo IT, Moyo VM, Mvundura E, et al. Association of pulmonary tuberculosis with increased dietary iron. J Infect Dis 2001; 184: 936-9.
102. Perry S, de Jong BC, Solnick JV, et al. Infection with Helicobacter pylori is associated with protection against tuberculosis. PLoS ONE 2010; 5: e8804.
103. Nagachar N, Ratledge C. Roles of trpE2, entC and entD in salicylic acid biosynthesis in Mycobacterium smegmatis. FEMS Microbiol Lett 2010; 308: 159-65.
104. De Voss JJ, Rutter K, Schroeder BG, Su H, Zhu Y, Barry CE, III. The salicylate-derived mycobactin siderophores of Mycobacterium tuberculosis are essential for growth in macrophages. Proc Natl Acad Sci U S A 2000; 97: 1252-7.
105. Nagachar N, Ratledge C. Knocking out salicylate biosynthesis genes in Mycobacterium smegmatis induces hypersensitivity to paminosalicylate (PAS). FEMS Microbiol Lett 2010; 311: 193-9.
106. Gold B, Rodriguez GM, Marras SA, Pentecost M, Smith I. The Mycobacterium tuberculosis IdeR is a dual functional regulator that controls transcription of genes involved in iron acquisition, iron storage and survival in macrophages. Mol Microbiol 2001; 42: 851-65.
107. Rodriguez GM, Smith I. Identification of an ABC transporter required for iron acquisition and virulence in Mycobacterium tuberculosis. J Bacteriol 2006; 188: 424-30.
108. Rodriguez GM. Control of iron metabolism in Mycobacterium tuberculosis. Trends Microbiol 2006; 14: 320-7.
109. Ryndak MB, Wang S, Smith I, Rodriguez GM. Mycobacterium tuberculosis High Affinity Iron Importer, IrtA, Contains an FAD Binding Domain. J Bacteriol 2010; 192: 861-9.
110. Skaar EP. The battle for iron between bacterial pathogens and their vertebrate hosts. PLoS Pathog 2010; 6: e1000949.
111. Tullius MV, Harmston CA, Owens CP, et al. Discovery and characterization of a unique mycobacterial heme acquisition system. Proc Natl Acad Sci U S A 2011; 108: 5051-6.
112. Jones CM, Niederweis M. Mycobacterium tuberculosis Can Utilize Heme as an Iron Source. J Bacteriol 2011; 193: 1767-70.
113. Rook GA, Taverne J, Leveton C, Steele J. The role of gammainterferon, vitamin D3 metabolites and tumour necrosis factor in the pathogenesis of tuberculosis. Immunology 1987; 62: 229-34.
114. Vidal M, Ramana CV, Dusso AS. Stat1-vitamin D receptor interactions antagonize 1,25-dihydroxyvitamin D transcriptional activity and enhance stat1-mediated transcription. Mol Cell Biol 2002; 22: 2777-87.
115. Stoffels K, Overbergh L, Giulietti A, Verlinden L, Bouillon R, Mathieu C. Immune regulation of 25-hydroxyvitamin-D3-1alphahydroxylase in human monocytes. J Bone Miner Res 2006; 21: 37-47.
116. Martineau AR, Honecker FU, Wilkinson RJ, Griffiths CJ. Vitamin D in the treatment of pulmonary tuberculosis. J Steroid Biochem Mol Biol 2007; 103: 793-8.
117. Liu PT, Stenger S, Li H, et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 2006; 311: 1770-3.
118. Wilkinson RJ, Lange C. Vitamin d and tuberculosis: new light on a potent biologic therapy? Am J Respir Crit Care Med 2009; 179: 740-2.
119. Liu PT, Stenger S, Tang DH, Modlin RL. Cutting edge: vitamin Dmediated human antimicrobial activity against Mycobacterium tuberculosis is dependent on the induction of cathelicidin. J Immunol 2007; 179: 2060-3.
120. Martineau AR, Wilkinson KA, Newton SM, et al. IFN-gamma-and TNF-independent vitamin D-inducible human suppression of mycobacteria: the role of cathelicidin LL-37. J Immunol 2007; 178: 7190-8.
121. Wilkinson RJ, Llewelyn M, Toossi Z, et al. Influence of vitamin D deficiency and vitamin D receptor polymorphisms on tuberculosis among Gujarati Asians in west London: a case-control study. Lancet 2000; 355: 618-21.
122. Martineau AR, Wilkinson RJ, Wilkinson KA, et al. A single dose of vitamin D enhances immunity to mycobacteria. Am J Respir Crit Care Med 2007; 176: 208-13.
123. Uitterlinden AG, Fang Y, van Meurs JB, Pols HA, van Leeuwen JP. Genetics and biology of vitamin D receptor polymorphisms. Gene 2004; 338: 143-56.
124. Valdivielso JM, Fernandez E. Vitamin D receptor polymorphisms and diseases. Clin Chim Acta 2006; 371: 1-12.
125. Wejse C, Olesen R, Rabna P, et al. Serum 25-hydroxyvitamin D in a West African population of tuberculosis patients and unmatched healthy controls. Am J Clin Nutr 2007; 86: 1376-83.
126. Wejse C, Gomes VF, Rabna P, et al. Vitamin D as supplementary treatment for tuberculosis: a double-blind, randomized, placebocontrolled trial. Am J Respir Crit Care Med 2009; 179: 843-50.
127. Warmelink G, van Altena R, Ten Hacken NH, van der Werf TS, van der Veer E. Nutritional status and vitamin D3 during antimicrobial treatment. Lancet 2011; 377: 1407-8.
128. Martineau AR, Timms PM, Bothamley GH, et al. High-dose vitamin D(3) during intensive-phase antimicrobial treatment of pulmonary tuberculosis: a double-blind randomised controlled trial. Lancet 2011; 377: 242-50.
129. Lalor MK, Floyd S, Gorak-Stolinska P, et al. BCG vaccination: a role for vitamin D? PLoS ONE 2011; 6: e16709.
130. Van Deun A, Martin A, Palomino JC. Diagnosis of drug-resistant tuberculosis: reliability and rapidity of detection. Int J Tuberc Lung Dis 2010; 14: 131-40.
131. [WHO. Treatment of tuberculosis: guidelines - 4th edition 2010
132. Schaberg T, Rebhan K, Lode H. Risk factors for side-effects of isoniazid, rifampin and pyrazinamide in patients hospitalized for pulmonary tuberculosis. Eur Respir J 1996; 9: 2026-30.
133. Tahaoglu K, Atac G, Sevim T, et al. The management of antituberculosis drug-induced hepatotoxicity. Int J Tuberc Lung Dis 2001; 5: 65-9.
134. Saukkonen JJ, Cohn DL, Jasmer RM, et al. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med 2006; 174: 935-52.
135. Sharma SK, Singla R, Sarda P, et al. Safety of 3 different reintroduction regimens of antituberculosis drugs after development of antituberculosis treatment-induced hepatotoxicity. Clin Infect Dis 2010; 50: 833-9.
136. Anonymus. The Global MDR-TB & XDR-TB Response Plan. WHO/HTM/TB/2007.387 20071-42.
137. Migliori GB, Loddenkemper R, Blasi F, Raviglione MC. 125 years after Robert Koch's discovery of the tubercle bacillus: the new XDR-TB threat. Is science enough to tackle the epidemic? Eur Respir J 2007; 29: 423-7.
138. Fitzwater SP, Caviedes L, Gilman RH, et al. Prolonged infectiousness of tuberculosis patients in a directly observed therapy shortcourse program with standardized therapy. Clin Infect Dis 2010; 51: 371-8.
139. Horne DJ, Royce SE, Gooze L, et al. Sputum monitoring during tuberculosis treatment for predicting outcome: systematic review and meta-analysis. Lancet Infect Dis 2010; 10: 387-94.
140. Fend R, Kolk AH, Bessant C, Buijtels P, Klatser PR, Woodman AC. Prospects for clinical application of electronic-nose technology to early detection of Mycobacterium tuberculosis in culture and sputum. J Clin Microbiol 2006; 44: 2039-45.
141. Kolk A, Hoelscher M, Maboko L, et al. Electronic-nose technology in diagnosis of TB patients using sputum samples. J Clin Microbiol 2010; 48: 4235-8.
142. Peter J, Green C, Hoelscher M, Mwaba P, Zumla A, Dheda K. Urine for the diagnosis of tuberculosis: current approaches, clinical applicability, and new developments. Curr Opin Pulm Med 2010; 16: 262-70.
143. Cok G, Parildar Z, Basol G, Kabaroglu C, Bayindir U, Habif S, Bayindir O. Pleural fluid neopterin levels in tuberculous pleurisy. Clin Biochem 2007; 40: 876-80.
144. Djoba Siawaya JF, Ruhwald M, Eugen-Olsen J, Walzl G. Correlates for disease progression and prognosis during concurrent HIV/TB infection. Int J Infect Dis 2007; 11: 289-99.
145. Agranoff D, Fernandez-Reyes D, Papadopoulos MC, et al. Identification of diagnostic markers for tuberculosis by proteomic fingerprinting of serum. Lancet 2006; 368: 1012-21.
146. Maher D, Dye C, Floyd K, et al. Planning to improve global health: the next decade of tuberculosis control. Bull World Health Organ 2007; 85: 341-7.
147. Ma Z, Lienhardt C, McIlleron H, Nunn AJ, Wang X. Global tuberculosis drug development pipeline: the need and the reality. Lancet 2010; 375: 2100-9.
148. Telenti A, Imboden P, Marchesi F, et al. Detection of rifampicinresistance mutations in Mycobacterium tuberculosis. Lancet 1993; 341: 647-50.
149. Boehme CC, Nabeta P, Hillemann D, et al. Rapid Molecular Detection of Tuberculosis and Rifampin Resistance. N Engl J Med 2010; 363: 1005-15.
150. Boehme CC, Nicol MP, Nabeta P, et al. Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. Lancet 2011; 377: 1495-505.
151. Pepper DJ, Marais S, Wilkinson RJ, et al. Clinical deterioration during antituberculosis treatment in Africa: incidence, causes and risk factors. BMC Infect Dis 2010; 10: 83.
152. Meintjes G, Wilkinson RJ, Morroni C, et al. Randomized placebocontrolled trial of prednisone for paradoxical tuberculosisassociated immune reconstitution inflammatory syndrome. AIDS 2010; 24: 2381-90.
153. Sereti I, Rodger AJ, French MA. Biomarkers in immune reconstitution inflammatory syndrome: signals from pathogenesis. Curr Opin HIV AIDS 2010; 5: 504-10.
154. Boulware DR, Hullsiek KH, Puronen CE, et al. Higher Levels of CRP, D-dimer, IL-6, and Hyaluronic Acid Before Initiation of Antiretroviral Therapy (ART) Are Associated With Increased Risk of AIDS or Death. J Infect Dis 2011; 203: 1637-46.